<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394497</url>
  </required_header>
  <id_info>
    <org_study_id>1635P</org_study_id>
    <nct_id>NCT01394497</nct_id>
  </id_info>
  <brief_title>Use of N-Acetylcysteine During Liver Procurement</brief_title>
  <official_title>Infusione Sistemica e Loco-regionale di N-Acetilcisteina Nel Prelievo di Fegato: Uno Studio Prospettico Randomizzato Controllato. Fase II.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera di Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized prospective study on the impact on the post-LT outcome by the infusion of
      N-acetylcysteine (NAC) during the liver procurement procedure, as an anti-oxidant agent to
      reduce the ischemia-reperfusion damage of organs for liver transplantation (LT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-oxidant agents have the potential to reduce the ischemia-reperfusion damage of organs
      for liver transplantation (LT). In this randomized prospective study, we seek to study the
      impact on the post-LT outcome of the infusion of N-acetylcysteine (NAC) during the liver
      procurement procedure.

      Potential grafts, assigned to adult candidates with chronic liver disease enlisted for first
      LT, will randomly be included in a one‑to‑one ratio with a sequential closed envelope
      single-blinded assignation procedure to either the NAC protocol or in the standard procedure
      (without NAC).

      The NAC protocol comprises: a systemic NAC infusion (30 mg/kg) one hour before the beginning
      of liver procurement; a loco-regional NAC infusion (300 mg through the portal vein) just
      before cross‑clamping.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft survival</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary graft dysfunction</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Liver Failure</condition>
  <condition>Liver Failure, Acute</condition>
  <condition>Liver Diseases</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>NAC procurement protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco‑regional infusion into the portal vein before cross‑clamping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard procurement procedure</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back‑table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcystein</intervention_name>
    <description>15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco‑regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross‑clamping.</description>
    <arm_group_label>NAC procurement protocol</arm_group_label>
    <other_name>Fluimucil (Zambon, Italy)</other_name>
    <other_name>ACC (Hexal AG)</other_name>
    <other_name>Acemuc (Betapharm, Germany)</other_name>
    <other_name>Acetyst (Ristert, Germany)</other_name>
    <other_name>Acetadote (Cumberland Pharmaceuticals)</other_name>
    <other_name>Asist (Bilim Pharmaceuticals, Turkey)</other_name>
    <other_name>Brunac eyedrops (Bruschettini, Italy)</other_name>
    <other_name>Fluimukan (Lek, Slovenia)</other_name>
    <other_name>Flumil (Pharmazam, Spain)</other_name>
    <other_name>Lysox (Menarini)</other_name>
    <other_name>Mucinac (Cipla, India)</other_name>
    <other_name>Mucohelp (Neiss Labs, India)</other_name>
    <other_name>Mucolysin (Sandoz)</other_name>
    <other_name>Mucomelt (Venus Remedies, India)</other_name>
    <other_name>MUCOMIX (Samarth Life Sciences, India)</other_name>
    <other_name>Mucomyst (Bristol-Myers Squibb)</other_name>
    <other_name>Nytex (Pharos,Indonesia)</other_name>
    <other_name>Parvolex (GSK)</other_name>
    <other_name>PharmaNAC (BioAdvantex Pharma Inc., North America)</other_name>
    <other_name>Rheunac (Tree Of Life, Israel)</other_name>
    <other_name>Solmucaïne (IBSA, Switzerland)</other_name>
    <other_name>Trebon N (Uni-pharma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all consecutive subjects with chronic liver disease undergoing first Liver
             Transplantation receiving deceased donor livers

        Exclusion Criteria:

          -  recipients with acute liver disease;

          -  paediatric patients or adult patients receiving a liver from a paediatric donor;

          -  patients undergoing multiple-organ transplantation;

          -  patients undergoing re-transplantation of the Liver;

          -  patients undergoing living donor Liver Transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Cillo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco D'Amico, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fegatochirurgia.com/</url>
    <description>Hepatobiliary surgery and Liver Transplantation Unit, University Hospital of Padua (Italy)</description>
  </link>
  <results_reference>
    <citation>D'Amico F, Vitale A, Gringeri E, Valmasoni M, Carraro A, Brolese A, Zanus G, Neri D, Boccagni P, Violi P, Pauletto A, D'Amico FE, D'Amico DF, Cillo U. SYSTEMIC AND LOCO-REGIONAL INFUSION OF N-ACETILCISTEINA DURING LIVER PROCUREMENT: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY (Abstract# 488), The International Liver Transplantation Society: 14th Annual International Congress, July 9-12, 2008, Paris, France. Liver Transplantation, 14: S1-S269. doi: 10.1002/lt.21569</citation>
  </results_reference>
  <results_reference>
    <citation>D'Amico F, Vitale A, Piovan D, Bertacco A, Ramirez Morales R, Chiara Frigo A, Bassi D, Bonsignore P, Gringeri E, Valmasoni M, Garbo G, Lodo E, D'Amico FE, Scopelliti M, Carraro A, Gambato M, Brolese A, Zanus G, Neri D, Cillo U. Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl. 2013 Feb;19(2):135-44. doi: 10.1002/lt.23527. Epub 2012 Sep 26.</citation>
    <PMID>22859317</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Padova</investigator_affiliation>
    <investigator_full_name>Prof. Umberto Cillo</investigator_full_name>
    <investigator_title>Director of the Hepatobiliary Surgery and Liver Transplantation Unit</investigator_title>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>Graft Survival</keyword>
  <keyword>Graft Rejection</keyword>
  <keyword>Primary Graft Dysfunction</keyword>
  <keyword>Tissue and Organ Harvesting</keyword>
  <keyword>Tissue and Organ Procurement</keyword>
  <keyword>Tissue Donors</keyword>
  <keyword>Cold Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

